<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00965289</url>
  </required_header>
  <id_info>
    <org_study_id>GOELAMS 074</org_study_id>
    <nct_id>NCT00965289</nct_id>
  </id_info>
  <brief_title>High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma</brief_title>
  <official_title>Front-line High-dose Chemotherapy (HDT) Combined With Rituximab for Adults With Aggressive Large B-cell Lymphoma (DLBCL) : Goelams 074 Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective pilot trial was proposed to patients with DLBCL, with IH or high adjusted IPI,
      up to the age of 60 y.o. This program consisted of 2 courses of high-dose R-CHOP-like
      regimen, followed by a course of high-dose methotrexate with cytarabin. For patients who
      achieved at least a PR, ASCT started with a BEAM regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Superiority of HDT with autologous stem cell transplantation (ASCT) in the upfront treatment
      of poor-risk DLBCL remains an option for intermediate-high (IH) or high IPI young adults. We
      updated results of the prospective trial Goelams 074 to evaluate long-term efficacy and
      toxicity in 42 patients who underwent HDT with ASCT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CR rate after 3 high dose chemotherapy courses</measure>
    <time_frame>safety/efficacy of chemotherapy treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR and PR rate at the end of the study treatment</measure>
    <time_frame>safety/efficacy of treatment30 days after the end of post ASCT aplasia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS,EFS and OS</measure>
    <time_frame>safety/efficacy of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of Rituximab combined with chemotherapy</measure>
    <time_frame>safety/efficacy of immunotherapy combined with chemotherapy treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>HDT combined with rituximab before ASCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study treatment consisted on 2 courses of high-dose R-CHOP-like regimen, followed by a course of high-dose methotrexate with cytarabin. For patients who achieved at least a PR, ASCT started with a BEAM regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab infusion on day 1 dose: 375mg/m²</description>
    <arm_group_label>HDT combined with rituximab before ASCT</arm_group_label>
    <other_name>Mabthera®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 60 y.o

          -  Aggressive Large B-Cell Lymphoma (CD20+)

          -  Ann Arbor stage III, IV

          -  IH or high adjusted IPI

          -  signed inform consent

        Exclusion Criteria:

          -  Age &lt; 18 ou &gt; 60 y.o

          -  other type of lymphoma

          -  serology VIH +

          -  other neoplasms apart from basal cell carcinoma or situ carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noel MILPIED, PD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU NANTES/GOELAMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2009</study_first_submitted>
  <study_first_submitted_qc>August 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2009</study_first_posted>
  <last_update_submitted>August 25, 2009</last_update_submitted>
  <last_update_submitted_qc>August 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pr Noel MILPIED</name_title>
    <organization>NANTES UNIVERSITY HOSPITAL /GOELAMS</organization>
  </responsible_party>
  <keyword>Aggressive large B-cell lymphoma (DLBCL)</keyword>
  <keyword>Intensive chemotherapy</keyword>
  <keyword>Rituximab</keyword>
  <keyword>ASCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

